Investigational New Drugs

, Volume 28, Issue 5, pp 634–640

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer

  • Stacy Moulder
  • Navneet Dhillon
  • Chaan Ng
  • David Hong
  • Jennifer Wheler
  • Aung Naing
  • Susan Tse
  • Amy La Paglia
  • Robert Dorr
  • Evan Hersh
  • Michelle Boytim
  • Razelle Kurzrock
PHASE I STUDIES

Summary

Purpose Imexon is an iminopyrrolidone that induces apoptosis and has synergistic activity with docetaxel in preclinical models. This trial was designed to establish the maximum tolerated dose (MTD) of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC). Patients and Methods 34 patients received protocol therapy. 26 patients received escalating doses of imexon given intravenously over 60 min on days 1–5 every 21 days. Docetaxel was administered intravenously at a fixed dose of 75 mg/m2 immediately following imexon on day 1 every 21 days. A 3+3 design was used with eight additional patients treated at MTD. Response was measured using RECIST. Results Seven dose levels of imexon were evaluated (390 mg/m2 to 1,700 mg/m2). The MTD was imexon 1,300 mg/m2 IV on days 1–5 in combination with docetaxel. Dose limiting toxicities were grade 3 non-cardiac chest pain and grade 3 diarrhea. Activity was seen in 4 patients [2 partial responses (NSCLC (PR=1), prostate cancer (PR=1)), 2 minor responses (MR=breast, NSCLC)]. Eleven patients had stable disease by RECIST (including the patients with MR; prostate cancer=6, NSCLC=3). Six (one with breast cancer, two with prostate cancer and three with NSCLC) demonstrated stable disease (SD) for ≥ 3 months. Conclusion The MTD of combination therapy is imexon 1,300 mg/m2 IV on days 1–5 with docetaxel 75 mg/m2 IV on day 1 of a 21 day treatment cycle. Demonstrated responses warrant further investigation in phase II trials of which a phase II trial in NSCLC is planned.

Keywords

Phase I Imexon Docetaxel Breast cancer Lung cancer Prostate cancer 

References

  1. 1.
    Iyengar BS, Dorr RT, Remers WA (2004) Chemical basis for the biological activity of imexon and related cyanoaziridines. J of Med Chem 47:218–23CrossRefGoogle Scholar
  2. 2.
    Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT (2000) Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60:749–58CrossRefPubMedGoogle Scholar
  3. 3.
    Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT (2001) Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544–51CrossRefPubMedGoogle Scholar
  4. 4.
    Dragovich T, Gordon M, Mendelson D et al (2007) Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25:1779–84CrossRefPubMedGoogle Scholar
  5. 5.
    Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT (2002) Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anti-cancer drugs 13:1031–42CrossRefPubMedGoogle Scholar
  6. 6.
    Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE (1992) Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238–44CrossRefPubMedGoogle Scholar
  7. 7.
    Pourpak A, Meyers RO, Samulitis BK et al (2006) Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-cancer drugs 17:1179–84CrossRefPubMedGoogle Scholar
  8. 8.
    Scott J, Dorr RT, Samulitis B, Landowski TH (2007) Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol 59:749–57CrossRefPubMedGoogle Scholar
  9. 9.
    Park JS, Yamamoto W, Sekikawa T et al (2002) Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 20:333–8PubMedGoogle Scholar
  10. 10.
    Iwao-Koizumi K, Matoba R, Ueno N et al (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422–31CrossRefPubMedGoogle Scholar
  11. 11.
    Dorr RT, Liddil JD, Klein MK, Hersh EM (1995) Preclinical pharmacokinetics and antitumor activity of imexon. Invest new drugs 13:113–6CrossRefPubMedGoogle Scholar
  12. 12.
    Bruno R, Hille D, Riva A et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–96PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Stacy Moulder
    • 1
    • 2
  • Navneet Dhillon
    • 2
  • Chaan Ng
    • 3
  • David Hong
    • 2
  • Jennifer Wheler
    • 2
  • Aung Naing
    • 2
  • Susan Tse
    • 2
  • Amy La Paglia
    • 4
  • Robert Dorr
    • 5
  • Evan Hersh
    • 5
  • Michelle Boytim
    • 5
  • Razelle Kurzrock
    • 2
  1. 1.Breast Medical OncologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Investigational Cancer Therapeutics (Phase I Program)University of Texas M. D. Anderson Cancer CenterHoustonUSA
  3. 3.Diagnostic RadiologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  4. 4.ABC LaboratoriesColumbiaUSA
  5. 5.AmpliMed CorporationTucsonUSA

Personalised recommendations